TMS Co

TMS Co Diluted EPS

The Diluted Earnings per Share of TMS Co (4891.T) as of Nov 5, 2026 is -18.85 JPY. In the previous year, Diluted Earnings per Share was -14.52 JPY — a change of 29.82% (lower).

Diluted EPS

-18.85JPY

YoY

29.82%

Last updated:

Diluted Earnings per Share of TMS Co is 2026 -18.85 JPY. Diluted Earnings per Share of TMS Co was 2025 -14.52 JPY. It decreases by 29.82% lower compared to the previous year.

The TMS Co Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2021
-15.86 JPY
Jan 1, 2022
32.16 JPY
Jan 1, 2023
-22.76 JPY
Jan 1, 2024
-23.80 JPY
Jan 1, 2025
-14.52 JPY
Jan 1, 2026
-18.85 JPY
The TMS Co Diluted EPS history
YEARDiluted EPSYoY
-18.85JPY+29.82%
-14.52JPY-39.00%
-23.80JPY+4.58%
-22.76JPY-170.77%
32.16JPY-302.79%
-15.86JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Diluted Earnings per Share of TMS Co is -18.85 JPY in 2026.

Diluted Earnings per Share of TMS Co changed from -14.52 JPY to -18.85 JPY, representing a 29.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share TMS Co since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TMS Co

All Key Metrics — TMS Co